key: cord-1026201-m9y1vae2
authors: Liu, Yiwei; Wang, Yingying; Wang, Xinming; Xiao, Yan; Chen, Lan; Guo, Li; Li, Jianguo; Ren, Lili; Wang, Jianwei
title: Development of two TaqMan real-time reverse transcription-PCR assays for the detection of severe acute respiratory syndrome coronavirus-2
date: 2020-07-23
journal: Biosaf Health
DOI: 10.1016/j.bsheal.2020.07.009
sha: d0fba6ffa27f70caaeda74d5d0c25de04acc7124
doc_id: 1026201
cord_uid: m9y1vae2

The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, was caused by a novel coronavirus (CoV), named severe acute respiratory syndrome CoV-2 (SARS-CoV-2). The rapid detection of viral nucleic acids is critical for the early identification of infected cases. We have developed two TaqMan real-time reverse transcription-PCR assays to detect SARS-CoV-2. The designed primers target the nucleocapsid (N) and open reading frame (ORF) 1b gene regions, where the probes discriminate SARS-CoV-2 from other human and animal CoVs. The sensitivities are one genomic copy per reaction for the N gene assay and ten copies for the ORF 1b gene assay. The overall linear detection ranges are 1–10(6) and 10–10(6) copies per reaction for the N gene assay and the ORF 1b gene assay, respectively. Surveillance of 23 suspected COVID-19 patients demonstrated that SARS-CoV-2 could be detected from 100% (23/23) and 62.5% (16/23) of clinical specimens by the N gene assay and the ORF 1b gene assay, respectively. All of the samples not detected by the ORF 1b gene assay were throat swabs, indicating a lower viral load in the upper respiratory tract and the relatively lower sensitivity of the ORF 1b gene assay. The assays developed in the present study offer alternative diagnostic tests for COVID-19.

In late 2019, a novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, Hubei province, China [1] [2] [3] . The etiological agent was later identified as a novel coronavirus (CoV), now named severe acute respiratory syndrome CoV-2 (SARS-CoV-2) [4] . Rapid and reliable diagnostic tests of SARS-CoV-2 were needed for quick confirmation of the viral infection and for the guidance of medical interventions [5, 6] . In response, several panels of TaqMan real-time reverse transcription-PCR (RT-PCR) assays for the detection of SARS-CoV-2 were quickly suggested by the World Health Organization, the Chinese Center for Disease Control and Prevention and some biotechnology companies.

The requirement for rapid and reliable diagnostics of SARS-CoV-2 is increasing to meet the demands of accurate diagnosis and to document infections [6, 7] . However, most of the currently developed TaqMan real-time RT-PCR assays for the detection of SARS-CoV-2 were designed as an emergency response and their analytical performance has not been reported in detail, including the sensitivity, specificity and linear detection range of the assays. Some assays were even developed in the absence of SARS-CoV-2 isolates or patient samples [5] . Comparisons with the currently available real-time RT-PCR assays are also lacking [5] .

To provide a more reliable choice for the rapid detection of SARS-CoV-2 and to comprehensively evaluate the analytical performance of the real-time RT-PCR assays, J o u r n a l P r e -p r o o f

The clinical specimens (sputum and throat swab) were taken from patients suspected of COVID-19 (one sample from each patient), and were kept in viral transport medium (VTM). All of the clinical specimens were treated in a Biosafety Level 3 laboratory. A total of 200 µl VTM were added into 600 µl Trizol LS for lysis, and subsequent RNA extraction was performed by using Direct-zol TM RNA MiniPrep (ZYMO RESEARCH, CA, USA) according to the manufacturer's instructions. The extracted RNA was resolved in a volume of 50 μl DNase/RNase-Free water and either tested immediately or stored at -80 °C.

The total nucleic acids were extracted by using a NucliSens easyMAG apparatus (bioMerieux, Marcy l′ Etoile, France) from respiratory samples positive for other common respiratory viruses, including human coronaviruses (NL63, OC43, 229E, and HKU1), influenza A and B, respiratory syncytial virus, parainfluenza 1 to 4, human metapneumovirus, rhinovirus, adenovirus, and bocavirus, which in the sample bank within our laborator, confirmed as reported previously [1, 8] . Table 1 ).

The TaqMan real-time RT-PCR assays were performed using TaqMan Fast Table 2 ). The Ct values increased as the N and ORF 1b RNA copies ranged from 10 6 to one copy in the reaction ( Figure 2 , Table 2 ). Strong linear correlations (r 2 = 0.9958 for the N gene assay and r 2 = 0.9963 for the ORF 1b gene assay) were obtained between Ct values and the quantity of RNA transcripts.

These results suggested that the developed assays possess high sensitivities and wide linear ranges in SARS-CoV-2 detection.

The reproducibility of the developed assays was then analyzed by assessing the intra-and inter-assay variabilities ( Table 3 ). Reproducibility reached 100% at one copy per reaction for the N gene assay and 10 copies per reaction for the ORF 1b gene assay. The coefficients of the mean Ct values within and between runs for the N gene assay were 0.20%-1.33% and 0.77%-2.45%, respectively, compared with 0.26%-4.45% and 0.49%-5.12%, respectively, for the ORF 1b gene assay. These results indicated the high reproducibility of the developed assays.

The amplification efficiencies of the assays were assessed through the amplification of RNA transcripts in the presence of exogenous nucleic acids from other common respiratory viruses, including influenza A and B, respiratory syncytial virus, parainfluenza virus 1-4, adenovirus, bocavirus, rhinovirus, and enterovirus.

Ten-fold serial dilutions of the RNA transcripts were prepared in RNase-free water (RNA transcript alone) and the pooled RNA from 15 SARS-CoV-2-negative human J o u r n a l P r e -p r o o f viruses (118%, slope = −2.92) ( Table 2 ). These results suggested that the amplification reaction was more efficient in the presence of RNA from other respiratory viruses.

To further evaluate the potential cross-reactivity with other human respiratory viruses, the developed TaqMan RT-PCR assays were examined using human respiratory samples positive for human coronaviruses (NL63, OC43, 229E, and HKU1), influenza A and B, respiratory syncytial virus, parainfluenza 1 to 4, human metapneumovirus, rhinovirus, adenovirus, and bocavirus. No cross reactivity was detected between the above viral nucleic acids for any of the developed RT-PCR assays (data not shown), demonstrating the high specificity of the developed assays.

The developed real-time RT-PCR assays were applied to the testing of 23 clinical specimens (including 11 throat swabs and 12 sputum specimens) from 23 suspected COVID-19 patients ( Table 4 , Figure S1 ). The N gene assay and the ORF 1b gene assay could detect SARS-CoV-2 from 100% (23/23) and 62.5% (16/23) of the clinical specimens, respectively. The ORF 1b gene assay could detect SARS-CoV-2 from 100% (12/12) of sputum samples and 36.4% (4/11) of throat swabs. The RNA copy number of the 23 samples were between 6.50E+01 and 1.10E+06 copies/ml calculated by the standard curve of ten-fold diluted N gene transcript, and from 2.05E+02 to J o u r n a l P r e -p r o o f 12], caution is needed when interpreting results with a Ct value higher than 35. False positive results could arise from slight mismatches between the primer/probe and template from the human genome or other sources. We addressed this by confirming the results by performing a repeat test when a weak positive result with a Ct value higher than 35 was obtained. The sensitivity of the N gene assay was 250 copies/ml, which were comparable to the commercial kits with sensitivities ranging from 1×10 2 to 1×10 3 copies/ml. J o u r n a l P r e -p r o o f

The rapid detection of viral nucleic acids is critical for early identification of the infected cases. We would like to develop sensitive and specific TaqMan real-time RT-PCR assays for detecting SARS-CoV-2 in clinical specimens, and analytically investigate the performance of them in detail.

The outbreak of SARS-CoV-2 caused pandemic globally. The requirement for rapid and reliable diagnostics of SARS-CoV-2 is increasing to meet the demand of accurate diagnosis and document infections. However, most of the currently developed TaqMan real time RT-PCR assays for the detection of SARS-CoV-2 were aided for emergency technology support, the analytical performance of which have not been reported in detail, including the sensitivity, specificity, linear detection range, etc.

Some assays were even developed in the absence of SARS-CoV-2 isolate or patients samples.

In this study we introduced TaqMan real-time reverse transcription-PCR assays to detect SARS-CoV-2, targeting to the nucleocapsid (N) and the open reading frame 1b (ORF 1b) gene region. The sensitivities are one genomic copy per reaction for the N gene assay and 10 copies for the ORF 1b gene assay. The overall linear detection ranges are 1-10 6 and 10-10 6 copies per reaction for the N gene assay and the ORF 1b Journal Pre-proof J o u r n a l P r e -p r o o f gene assay, respectively. The specificities are also discussed. All of the samples not detected by the ORF 1b gene assay were throat swabs, indicating a lower viral load in upper respiratory tract and a relative low sensitivity of the ORF 1b gene assay.

We developed two TaqMan real-time RT-PCR assays permitting rapid, sensitive, and specific detection of SARS-CoV-2 in clinical specimens.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Novel coronavirus: From discovery to clinical diagnostics

Asymptomatic cases in a family cluster with SARS-CoV-2 infection

Prevalence of human respiratory viruses in adults with acute respiratory tract infections in Beijing

Combination of RT-qPCR Testing and Clinical Features For Diagnosis of COVID-19 facilitates management of SARS-CoV-2 Outbreak

Emerging understandings of 2019-nCoV

Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22

Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus

We would like to thank the clinicians who contributed to sample collection and